文献速递药物相互作用

一种区分口服代谢药物生物利用度与清除率变化的简易方法

A Simple Methodology to Differentiate Changes in Bioavailability From Changes in Clearance Following Oral Dosing of Metabolized Drugs.
PubMed 文献 · Clin Pharmacol Ther · 2020-04-19

该研究提出一种简易方法,利用表观分布容积变化倒数估算口服药物相互作用中生物利用度(F)的独立变化,再结合表观清除率(CL/F)变化推算清除率(CL)变化。基于咪达唑仑和阿哌沙班与五种CYP3A4抑制剂/诱导剂的口服与静脉数据验证,口服数据预测的CL和F变化与静脉研究观察值接近,表明该方法可在仅有口服数据时合理区分F与CL变化。

要点

  • 对严格代谢性口服药物相互作用,假设分布容积不变,可用其变化倒数估算F变化。
  • 结合CL/F变化可进一步推算CL变化,无需静脉相互作用研究。
  • 咪达唑仑和阿哌沙班口服数据预测的CL与F变化与静脉研究观察值接近。

核心结论

  • 仅基于口服数据即可合理区分代谢性药物相互作用中生物利用度变化与清除率变化。

研究设计与样本

  • 方法学验证研究,分析咪达唑仑和阿哌沙班与五种已知CYP3A4抑制剂或诱导剂的口服及静脉药物相互作用数据。

主要发现

  • 基于口服数据预测的CL和F变化与基于静脉研究观察到的变化 reasonably close。

关键数值与推荐

  • 对严格代谢性相互作用,假设分布容积在两阶段间不变,其变化倒数可提供F变化的充分估计。

临床怎么用

  • 在仅有口服数据时,可用该方法评估代谢性药物相互作用中F与CL的独立变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Accurately discriminating changes in clearance (CL) from changes in bioavailability (F) following an oral drug-drug interaction is difficult without carrying out an intravenous interaction study. This may be true for drugs that are clinically significant transporter substrates; however, for interactions that are strictly metabolic, it has been recognized that volume of distribution remains unchanged between both phases of the interaction study. With the understanding that changes in volume of distribution will be minimal for metabolized drugs, the inverse of the change in apparent volume of distribution can provide adequate estimates of the change in bioavailability alone. Utilization of this estimate of F change in tandem with the observed apparent clearance (CL/F) change in an oral drug-drug interaction can provide an estimate of the change in clearance alone. Here, we examine drug-drug interactions involving five known inhibitors and inducers of cytochrome P450 3A4 isozyme on victim drugs midazolam and apixaban for which the interaction was carried out both orally and intravenously, allowing for evaluation of this methodology. Predictions of CL and F changes based on oral data were reasonably close to observed changes based on intravenous studies, demonstrating that this simple yet powerful methodology can reasonably differentiate changes in F from changes in CL for oral metabolic drug interactions when only oral data are available. Utilization of this relatively simple methodology to evaluate DDIs for orally dosed drugs will have a significant impact on how DDIs are interpreted from a drug development and regulatory perspective.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Sodhi JK, Benet LZ. A Simple Methodology to Differentiate Changes in Bioavailability From Changes in Clearance Following Oral Dosing of Metabolized Drugs. Clin Pharmacol Ther. 2020. PMID: 32150643. doi:10.1002/cpt.1828

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。